Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Amgen Wraps Up Phase III Trial For Soliris Biosimilar
Amgen Able To Launch Eculizumab Biosimilar In 2025 Under Settlement Agreement
Aug 29 2022
•
By
Rosalind Rei
Amgen has several biosimilars in Phase III development • Source: Shutterstock
More from Biosimilars
More from Products
